Related Experiment Video
Updated: May 27, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter
Eun Kyung Lee1, Ji Hye Chae, Myung-Soo Kang
1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
Insights
Epstein-Barr virus (EBV) LMP1 downregulates CD99 in Hodgkin's lymphoma (HL) by activating NF-κB2. This pathway, involving Sp1 binding sites, is crucial for pathogenic Reed-Sternberg cell development.
Area of Science:
- Molecular Biology
- Oncology
- Virology
Background:
- CD99 antigen downregulation is linked to Hodgkin's lymphoma (HL) pathogenesis.
- Epstein-Barr virus (EBV) LMP1 protein influences NF-κB signaling and Sp1 transcriptional activity.
- Reed-Sternberg cells, characteristic of HL, are associated with CD99 downregulation.
Purpose of the Study:
- To investigate the role of EBV LMP1 and NF-κB signaling in CD99 promoter regulation.
- To identify specific NF-κB subunits involved in CD99 repression.
- To elucidate the mechanism by which LMP1-mediated NF-κB affects CD99 transcription.
Main Methods:
- Reporter gene assays to measure CD99 promoter activity.
- Transfection experiments with EBV LMP1, NF-κB subunits, and kinase mutants.
- Analysis of CD99 promoter activity in wild-type and knockout mouse embryonic fibroblasts (MEFs).
- Site-directed mutagenesis and synthetic reporter assays targeting Sp1-binding sites.
Main Results:
- EBV LMP1, CD30, CD40, and NF-κB-inducing kinase (NIK) repress the CD99 promoter.
- NF-κB2 (p52) subunit is essential for LMP1-mediated CD99 repression.
- LMP1-mediated repression of CD99 requires NF-κB2 and functional Sp1-binding sites.
- Basal CD99 promoter activity is elevated in IKKα and IKKβ deficient cells.
Conclusions:
- NF-κB2 activation by EBV LMP1 plays a critical role in CD99 gene transcription repression.
- The findings highlight a specific molecular mechanism contributing to HL pathogenesis.
- Targeting the LMP1-NF-κB2-Sp1 pathway could offer therapeutic strategies for Hodgkin's lymphoma.
Abstract:
Downregulation of the CD99 antigen on the surface of Hodgkin's lymphoma (HL) cells via EBV LMP1-mediated NF-κB suppression of Sp1 transcriptional activity is known to be associated with the appearance of pathogenic Reed-Sternberg cells. Here, we show that in addition, EBV LMP1 heterologous NF-κB activators such as CD30 and CD40 repress the CD99 promoter, which contains multiple Sp1-binding sites but no NF-κB binding sites. In addition, NF-κB-inducing kinase (NIK) repressed the CD99 promoter while NIK kinase mutants and JNK inhibitory protein failed to do so. Of the NF-κB subunits, NF-κB2 (p52) alone or in combination with other Rel subunits consistently inhibited the CD99, while NF-κB1 (p50) showed a marginal repressive effect. Furthermore, while transfection of LMP1 repressed the CD99 promoter in wild-type or NF-κB1 deficient MEFs, the same repression was not observed in NF-κB2 (p52)-deficient MEFs, indicating that NF-κB2 (p52) is required for LMP1-mediated repression of the CD99 promoter. Consistently, basal activity of the CD99 promoter was significantly higher in IKKα(-/-) and IKKβ(-/-) MEFs, but not in IKKΓ(-/-) MEFs compared to the wild-type control MEFs. Sp1-binding sites were directly used in the repression, because a synthetic Sp1 reporter with 10 Sp1-binding sites from the CD99 promoter was repressed by LMP1 or p52 transfection. These data indicate that LMP1-mediated NF-κB2 exhibits the major inhibitory role in the transcription at the CD99 promoter.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
RNA Polymerase II Accessory Proteins
Methods of Nuclear Reprogramming

